Details

New and innovative digital health solutions are trying to transform the model of care in cancer by concentrating their services not only for HCPs but also for patients.

Nevertheless, the sophistication level of digital oncology solutions today is well behind of other digital health market segments. In recent years, Pharma and digital health companies have started to form alliances, such as Eli Lilly and Sidekick Health, to co-develop patient focused digital health tools that support diagnosis, self-management, and treatment adherence.

Solutions vary from simple pill reminders and education tools to advanced monitoring devices that effectively facilitate HCP, patient, and caregiver communication. Some of these solutions raised significant awareness among the global target group reporting more than 1 million downloads in one year.

At present, above 60% of the available digital oncology solutions offer services for all the cancer patients, with skin and breast cancer being the top specialized cancer treatment solutions.

Clinical efficacy results from the digital oncology solutions, regarding better patient outcomes, exists but are limited in terms of number of trials and quality studies. The following years will show an increasing number of studies that cover not only endpoints like mobile oncology app usage but also reduced pain levels or improved adherence at a larger scale.

Allis's Digital Oncology Channel will help you with both continuously tracking clinical study results from digital oncology solutions and keeping tabs on new service offerings and partnerships between digital health and Pharma companies in this market segment.

Together with our Analysts, you can deepen your digital oncology market intelligence by connecting the dots and putting data into a context.